Cargando…
Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data
OBJECTIVE: To compare drug survival of biological therapies in patients with rheumatoid arthritis (RA), and analyze the determinants of discontinuation probabilities and switches to other biological therapies. MATERIALS AND METHODS: Consecutive RA patients initiating first biological treatment in on...
Autores principales: | Brodszky, Valentin, Bíró, Anikó, Szekanecz, Zoltán, Soós, Boglárka, Baji, Petra, Rencz, Fanni, Tóthfalusi, László, Gulácsi, László, Péntek, Márta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317255/ https://www.ncbi.nlm.nih.gov/pubmed/28243133 http://dx.doi.org/10.2147/CEOR.S124381 |
Ejemplares similares
-
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
por: Gulácsi, László, et al.
Publicado: (2017) -
Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
por: Gulácsi, László, et al.
Publicado: (2017) -
Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data
por: Baji, Petra, et al.
Publicado: (2020) -
Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison
por: Baji, Petra, et al.
Publicado: (2014) -
Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies
por: Zrubka, Zsombor, et al.
Publicado: (2019)